Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data For Stro-002 Antibody-Drug…
Sutro Biopharma, Inc. announced updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from its on-going Phase 1…
Read More...
Read More...
